Banner
Biotechnology

Amgen, Inc. (Nadaq: AMGN) – FYE 12/2021 – FAIRLY VALUED – The stock is currently trading at levels above my most recent $167 initiate target, but below my most recent $298 reduce target. Please See Linked PDF Worksheet.
Revised on 04/13/2022

Emergent BioSolutions, Inc. (NYSE: EBS) – FYE 12/2019 – OVER VALUED – The stock is currently trading at levels above my most recent $61 terminate target. Please See Linked PDF Worksheet.
Revised on 01/27/2021

Gilead Sciences, Inc. (Nasdaq: GILD) – FYE 12/2021 – UNDER VALUED – The stock is currently trading at levels below my most recent $81 initiate target. Please See Linked PDF Worksheet.
Revised on 08/02/2022

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) – FYE 12/2021 – UNDER VALUED – The stock is currently trading at levels below my most recent $938 initiate target. Please See Linked PDF Worksheet.
Revised on 07/29/2022

Repligen Corporation (Nasdaq: RGEN) – FYE 12/2021 – OVER VALUED – The stock is currently trading at levels above my most recent $89 terminate target. Please See Linked PDF Worksheet.
Revised on 08/11/2022

Please note that worksheets are updated basis the most current SEC 10-K ANNUAL filing.